Table 3.
Characteristics of psychiatric consultations by period and year.
Lockdown period | Post-lockdown period | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2019 | 2020 | 2019 | 2020 | ||||||||
No. | % | No. | % | p-value | No. | % | No. | % | p-value | ||
Admitted to GHPU | 740 | 38.3% | 441 | 36.6% | 0.318 | 465 | 37.1% | 513 | 49.8% | <0.001 | |
Compulsory admission | 109 | 5.6% | 87 | 7.2% | 0.075 | 67 | 5.3% | 82 | 8.0% | 0.011 | |
Diagnosis made by the psychiatrist | <0.001 | 0.001 | |||||||||
No psychiatric disorder | 26 | 1.3% | 31 | 2.6% | * | 15 | 1.2% | 17 | 1.7% | ||
Psychotic episode | 241 | 12.5% | 143 | 11.9% | 155 | 12.4% | 136 | 13.3% | |||
(Hypo)manic agitation | 95 | 4.9% | 36 | 3.0% | * | 48 | 3.8% | 57 | 5.6% | * | |
Psychomotor agitation | 449 | 23.3% | 287 | 23.8% | 316 | 25.2% | 241 | 23.5% | |||
Depression | 205 | 10.6% | 81 | 6.7% | * | 112 | 8.9% | 94 | 9.2% | ||
Anxiety | 384 | 19.9% | 262 | 21.7% | 255 | 20.3% | 149 | 14.5% | * | ||
Adjustment disorder/Distress | 76 | 3.9% | 30 | 2.5% | * | 53 | 4.2% | 42 | 4.1% | ||
Suicidal ideation/attempt | 211 | 10.9% | 133 | 11.0% | 123 | 9.8% | 131 | 12.8% | * | ||
Substance use disorders | 133 | 6.9% | 111 | 9.2% | * | 113 | 9.0% | 88 | 8.6% | ||
Delirium | 42 | 2.2% | 24 | 2.0% | 29 | 2.3% | 19 | 1.9% | |||
Other | 69 | 3.6% | 67 | 5.6% | * | 35 | 2.8% | 51 | 5.0% | * | |
Suicidality | 0.004 | 0.003 | |||||||||
Absent/non-detectable | 1502 | 83.2% | 1046 | 86.7% | * | 944 | 85.0% | 739 | 79.3% | * | |
Ideation or plans | 179 | 9.9% | 78 | 6.5% | * | 91 | 8.2% | 108 | 11.6% | * | |
Suicide attempt | 124 | 6.9% | 83 | 6.9% | 75 | 6.8% | 85 | 9.1% | * | ||
Pharmacological treatment | |||||||||||
Neuroleptics | 240 | 12.4% | 212 | 17.6% | <0.001 | 170 | 13.6% | 180 | 17.5% | 0.010 | |
Lithium/mood stabilizers | 165 | 8.5% | 106 | 8.8% | 0.818 | 102 | 8.1% | 93 | 9.0% | 0.446 | |
Antidepressants | 211 | 10.9% | 94 | 7.8% | 0.004 | 135 | 10.8% | 112 | 10.9% | 0.934 | |
Benzodiazepines | 665 | 34.4% | 465 | 38.5% | 0.020 | 416 | 33.2% | 421 | 40.9% | <0.001 | |
Ketamine/propofol/ midazolam | 108 | 5.6% | 52 | 4.3% | 0.111 | 70 | 5.6% | 42 | 4.1% | 0.098 |
Significant post-hoc pairwise comparisons.